[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339705-105":59,"doc-detail-339705-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinicopathological-correlation-of-insulin-like-growth-factor-binding-protein-3-and-their-death-receptor-in-patients-with-gastric-cancer","Clinicopathological correlation of insulin-like growth factor binding protein 3 and their death receptor in patients with gastric cancer","","The study evaluates the clinical and pathological relevance of insulin-like growth factor binding protein 3 (IGFBP-3) and its novel death receptor (IGFBP-3R) in gastric cancer. Sixty-eight gastric cancer samples were analyzed using quantitative real-time RT-PCR and western blotting to measure IGFBP-3/IGFBP-3R expression, then to link expression levels with prognostic factors. Tumor tissues showed reduced IGFBP-3 and IGFBP-3R. IGFBP-3 reduction associated with lymph node metastasis and TNM staging, while IGFBP-3R correlated with tumor size, metastasis, differentiation, TNM class, and stage-dependent downregulation. Low IGFBP-3R mRNA closely related to survival outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinicopathological-correlation-of-insulin-like-growth-factor-binding-protein-3-and-their-death-receptor-in-patients-with-gastric-cancer/339705/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinicopathological-correlation-of-insulin-like-growth-factor-binding-protein-3-and-their-death-receptor-in-patients-with-gastric-cancer/339705.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s primary goal regarding IGFBP-3 and IGFBP-3R in gastric cancer?","Question",{"text":112,"@type":113},"To determine whether IGFBP-3 and its novel death receptor IGFBP-3R have prognostic value and how their expression relates to clinicopathological features in gastric cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were IGFBP-3 and IGFBP-3R expressions measured in the patient samples?",{"text":117,"@type":113},"IGFBP-3 and IGFBP-3R expression levels were assessed by quantitative real-time polymerase chain reaction (RT-PCR) and western blotting, using tumor tissues compared with normal adjacent tissues.",{"name":119,"@type":110,"acceptedAnswer":120},"Which clinicopathological factors were associated with IGFBP-3 and IGFBP-3R expression?",{"text":121,"@type":113},"IGFBP-3 reduction was associated with lymph node metastasis and TNM staging. IGFBP-3R expression correlated with tumor size, lymph node metastasis, differentiation, TNM classification, and showed stage-dependent downregulation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339705,1790184174,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Clinicopathological correlation of insulin-like growth factor binding protein 3 and their death receptor in patients with gastric cancer  \nAmir Ansari1, Ali Gheysarzadeh2, Ali Sharifi3, and Mohammad Reza Mofid1,*  \n1Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of  \nMedical Sciences, Isfahan, I.R. Iran.  \n2Department of Biochemistry, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran.  \n3 Department of Internal Medicine, School of Medicine, Shahid Mostafa Khomeini Hospital, Ilam University of Medical  \nSciences, Ilam, Iran.  \nAbstract  \nBackground and purpose: The insulin-like growth factor binding protein 3 (IGFBP-3) and its novel death receptor (IGFBP-3R) have been exhibited to have tumor suppressor effects. Despite their prognostic value in some cancers, they have not been elucidated in gastric cancer.  \nExperimental approach: We collected 68 samples from patients with gastric cancer. IGFBP-3 and IGFBP- 3R expression levels were evaluated with quantitative real-time polymerase chain reaction (RT-PCR) and western blotting in patients. The relationship between prognostic factors and IGFBP-3/IGFBP-3R expression was also evaluated.  \nFindings/Results: Our results showed that IGFBP-3 and IGFBP-3R expression was reduced significantly in tumor tissues. We found that there was an association between the reduction of IGFBP-3 with lymph node metastasis and tumor-node-metastasis (TNM) staging. Besides, IGFBP-3R expression was associated with tumor size, lymph node metastasis, differentiation, and TNM classification. Interestingly, we presented that the downregulation of IGFBP-3R was stage-dependent. In survival analysis, our findings showed that low levels ofIGFBP-3R mRNA expression exhibited a close correlation with survival rate.  \nConclusion and implications: The findings ofthis study showed that the expression levels of IGFBP-3 and IGFBP-3R are valuable prognostic factors. Despite the potential of IGFBP-3, IGFBP-3R plays a significant role as a prognostic factor in gastric cancer. However, these findings need to be developed and confirmed by further studies.  \nKeywords: Gastric cancer; IGFBP-3; IGFBP-3R; Prognostic factor; TNM classification.  \nINTRODUCTION  \nGastric cancer (GC) is known as the fourth most common malignancy and the third cause of cancer-related death all over the world (1) . The 5-year survival of gastric cancer patients with adjuvant treatment in some cases can be extended to than 31%(2) . Poor prognosis, inconspicuous symptoms, and lack of effective diagnosis in an early stage of GC. GC identification usually takes place just after its symptoms are represented in a patient with advanced stage (3) . Therefore, understanding the molecular mechanism of cancer progression can  \n*Corresponding author: M.R. Mofid  \nTel: +98-3137927047, Fax: +98-3136680011  \n[Email: mofid@pharm.mui.ac.ir](Email: mofid@pharm.mui.ac.ir)  \nimprove the development of novel treatment strategies (4) .  \nInsulin-like growth factor-binding protein 3 (IGFBP-3) has been identified as a conserved and multi-functional protein that can bind to 80% ofIGF-I and IGF-II with high affinity and regulate IGF signaling (5) . The main function of IGFBP-3 has been identified in a wide variety of cancers (6) . This is the most abundant secreted protein of the IGFBPs family and participates in an IGF-dependent/independent manner.  \n\n| Access this article online |  |\n| --- | --- |\n| | Website: [http://rps.mui.ac.ir](http://rps.mui.ac.ir) |\n|  | DOI: 10.4103/1735-5362.394819 |\n\nIGFBP-3 has been shown to induce apoptosis in an IGF-independent action (7) . To determine the specific receptor ofIGFBP-3, for the first time, Kim et al. demonstrated that IGFBP-3 can bind to the cell surface-specific receptor by yeast two-hybrid screening (8) . Also, it was demonstrated that the IGFBP-3 receptor (IGFBP-3R) is widely expressed inmost tissues. It contains 240 amino acid residues in length and inter","cbCairTkKG528T2m","https://ap.wps.com/l/cbCairTkKG528T2m","pdf",889352,11,"English","# Abstract\n## Background and purpose\n## Experimental approach\n## Findings/Results\n## Conclusion and implications\n# Introduction\n# Materials and methods\n## Tissue samples","[{\"question\":\"What is the study’s primary goal regarding IGFBP-3 and IGFBP-3R in gastric cancer?\",\"answer\":\"To determine whether IGFBP-3 and its novel death receptor IGFBP-3R have prognostic value and how their expression relates to clinicopathological features in gastric cancer.\"},{\"question\":\"How were IGFBP-3 and IGFBP-3R expressions measured in the patient samples?\",\"answer\":\"IGFBP-3 and IGFBP-3R expression levels were assessed by quantitative real-time polymerase chain reaction (RT-PCR) and western blotting, using tumor tissues compared with normal adjacent tissues.\"},{\"question\":\"Which clinicopathological factors were associated with IGFBP-3 and IGFBP-3R expression?\",\"answer\":\"IGFBP-3 reduction was associated with lymph node metastasis and TNM staging. IGFBP-3R expression correlated with tumor size, lymph node metastasis, differentiation, TNM classification, and showed stage-dependent downregulation.\"}]","Clinicopathological correlation of insulin-like growth factor binding protein 3 and their death receptor in patients with gastric cancer | PDF",1790031715,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b16d17f3db1cc7c56e50d8c37a5932f.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/370ac374fbf5ece25379d5387a7f995b.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f98526a91167307eb490feb256bf2ca8.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dd0263d31b9c8338a2e5251a51a2d40.webp",980,1385]